SG11202107850VA - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
SG11202107850VA
SG11202107850VA SG11202107850VA SG11202107850VA SG11202107850VA SG 11202107850V A SG11202107850V A SG 11202107850VA SG 11202107850V A SG11202107850V A SG 11202107850VA SG 11202107850V A SG11202107850V A SG 11202107850VA SG 11202107850V A SG11202107850V A SG 11202107850VA
Authority
SG
Singapore
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
SG11202107850VA
Inventor
Anne Elizabeth O'hagan
Porre Peter Marie Z De
Anjali Narayan Avadhani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11202107850VA publication Critical patent/SG11202107850VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
SG11202107850VA 2019-02-12 2020-02-11 Cancer treatment SG11202107850VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19176575 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Publications (1)

Publication Number Publication Date
SG11202107850VA true SG11202107850VA (en) 2021-08-30

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107850VA SG11202107850VA (en) 2019-02-12 2020-02-11 Cancer treatment

Country Status (15)

Country Link
US (1) US20220168298A1 (en)
EP (1) EP3923942A1 (en)
JP (1) JP2022521173A (en)
KR (1) KR20210126654A (en)
CN (1) CN113423402A (en)
AU (1) AU2020223467A1 (en)
BR (1) BR112021015686A2 (en)
CA (1) CA3126959A1 (en)
IL (1) IL285466A (en)
JO (1) JOP20210216A1 (en)
MA (1) MA54932A (en)
MX (1) MX2021009670A (en)
SG (1) SG11202107850VA (en)
TW (1) TW202045173A (en)
WO (1) WO2020165181A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022125967A2 (en) * 2020-12-11 2022-06-16 Erasca, Inc. Combination therapies for the treatment of cancer
CN112957368A (en) * 2021-04-02 2021-06-15 南昌大学 New application of sevelamer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3365335B1 (en) * 2015-10-23 2024-02-14 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
JOP20190280A1 (en) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv Fgfr2 inhibitors for the treatment of cholangiocarcinoma
PT3576740T (en) * 2017-12-20 2023-08-18 Janssen Pharmaceutica Nv Cancer treatment

Also Published As

Publication number Publication date
CN113423402A (en) 2021-09-21
KR20210126654A (en) 2021-10-20
BR112021015686A2 (en) 2021-10-26
CA3126959A1 (en) 2020-08-20
EP3923942A1 (en) 2021-12-22
JP2022521173A (en) 2022-04-06
MX2021009670A (en) 2021-09-08
US20220168298A1 (en) 2022-06-02
WO2020165181A1 (en) 2020-08-20
JOP20210216A1 (en) 2023-01-30
IL285466A (en) 2021-09-30
AU2020223467A1 (en) 2021-08-05
TW202045173A (en) 2020-12-16
MA54932A (en) 2021-12-22

Similar Documents

Publication Publication Date Title
ZA202005847B (en) Cancer therapy
PT3576740T (en) Cancer treatment
GB201903546D0 (en) Cancer treatment
IL287652A (en) Cancer treatment
GB201820660D0 (en) Cancer treatments
GB201905780D0 (en) Cancer therapy
GB201706451D0 (en) Cancer treatment
IL285466A (en) Cancer treatment
IL274626A (en) Cancer treatment
IL268463A (en) Cancer treatment
IL288035A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
GB201819920D0 (en) Cancer treatment
GB201914296D0 (en) Treatment
GB201913957D0 (en) Cancer
GB201910644D0 (en) Cancer Treatment
GB201907149D0 (en) Cancer treatment
GB201811431D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
GB201901368D0 (en) Cancer therapy
GB201907204D0 (en) Cancer treatment 3
GB201907150D0 (en) Cancer treatment 2
EP4025203A4 (en) Cancer treatment
AU2019903263A0 (en) Cancer treatment
GB201918815D0 (en) Treatment of cancer